Innova Captab reported robust Q3 FY26 results, with revenue up by 42% YoY and 27% YoY for 9M FY26. This growth was fueled by strong performance in both the CDMO and Branded Generics segments. The company also received GMP compliance certificates, bolstering its international reach. EBITDA for Q3 FY26 stood at ₹71.1 crore.
Financial Performance Highlights
Innova Captab delivered strong revenue growth in Q3 FY26, with a 42% YoY increase, and a 27% YoY increase for the nine-month period. This performance is attributed to disciplined execution across operations.
Key Financials:
- Revenue: Increased to ₹1,244 crore.
- EBITDA: Stood at ₹198 crore with a margin of 15.9%.
- PAT: Reached ₹128 crore with a margin of 10.3%.
Segment Performance
The company witnessed growth across its business segments:
- CDMO Operations: Strong YoY growth of 29% in Q3 FY26 and 18% in 9M FY26.
- Branded Generics: Sharp YoY growth of 79% in Q3 FY26 and 56% in 9M FY26, driven by expanded geographical footprint.
Strategic Developments
Innova Captab received GMP compliance certificates from UK-MHRA for the Cephalosporin, Baddi unit and from PIC/s (SMDC, Ukraine) for the Jammu facility.
Capacity Expansion
The company is expanding its manufacturing capabilities with new facilities and inorganic acquisitions:
- New multipurpose facility in Kathua, Jammu, was commercialized in January 2025.
Future Outlook
Innova Captab is focused on driving consistent, high-quality growth and executing its long-term vision for stakeholder value creation. They expect to benefit from capacity expansion in the coming years.
Source: BSE
